Clinical Trials Logo
  1. Home
  2. Other
  3. NCT04690374
  4. Details
NCT04690374 Clinical Trial

Registry to Collect Health Information About Desmoplastic Small Round Cell Tumor

Desmoplastic Small Round Cell Tumor Clinical Trial

Official title:
Registry for Patients With Desmoplastic Small Round Cell Tumor

Clinical Trial Details — Status: Recruiting

Administrative data
NCT number NCT04690374
Other study ID # 20-551
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date December 22, 2020
Est. completion date December 2027

Study information
Verified date January 2024
Source Memorial Sloan Kettering Cancer Center
Contact Emily Slotkin, MD
Phone 1-833-675-5437
Email slotkine@mskcc.org
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

This study is a patient registry of people with Desmoplastic Small Round Cell Tumor (DSRCT). A patient registry is a collection of health information about a group of people, and it is usually focused on a specific diagnosis or disease. The purpose of this registry is to create a database- a collection of information-or better understanding DSRCT. Researchers will use the information from this database to learn more about DSRCT and for current and future research on DSRCT.

Recruitment information / eligibility
Status Recruiting
Enrollment 250
Est. completion date December 2027
Est. primary completion date December 2027
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: - Participants must have a diagnosis of desmoplastic small round cell tumor - Participants may be of any age as long as the appropriate consent and assent may be obtained - Willing to provide historical and longitudinal clinical data Exclusion Criteria: - Participant unwilling to provide consent or share historical and longitudinal clinical data

Study Design

Related Conditions & MeSH terms

  • Desmoplastic Small Round Cell Tumor

Locations
Country Name City State
United States Memorial Sloan Kettering Cancer Center (All Protocol Activities) New York New York

Sponsors (1)
Lead Sponsor Collaborator
Memorial Sloan Kettering Cancer Center

Country where clinical trial is conducted

United States, 

Outcome
Type Measure Description Time frame Safety issue
Primary Registry to Collect Health Information About Desmoplastic Small Round Cell Tumor The aim of this study is the collection of data. 7 years
See also
  Status Clinical Trial Phase
Not yet recruiting NCT06456359 - Pasireotide as Maintenance Treatment in Synovial Sarcoma and Desmoplastic Small Round Cell Tumor Phase 2
Active, not recruiting NCT04095221 - A Study of the Drugs Prexasertib, Irinotecan, and Temozolomide in People With Desmoplastic Small Round Cell Tumor and Rhabdomyosarcoma Phase 1/Phase 2
Active, not recruiting NCT02834169 - French National Registry of Rare Peritoneal Surface Malignancies N/A
Active, not recruiting NCT03600649 - Clinical Trial of SP-2577 (Seclidemstat) in Patients With Relapsed or Refractory Ewing or Ewing-related Sarcomas Phase 1
Recruiting NCT03618381 - EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults Phase 1
Recruiting NCT04897321 - B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR) Phase 1
Recruiting NCT05918640 - Lurbinectedin in FET-Fused Tumors Phase 1/Phase 2
Terminated NCT04901806 - Study of PBI-200 in Subjects With NTRK-Fusion-Positive Solid Tumors Phase 1
Recruiting NCT04022213 - A Study of the Drug I131-Omburtamab in People With Desmoplastic Small Round Cell Tumors and Other Solid Tumors in the Peritoneum Phase 2
Active, not recruiting NCT04483778 - B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults Phase 1
Active, not recruiting NCT04145349 - CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Desmoplastic Small Round Cell Tumor Phase 1/Phase 2
Suspended NCT01125449 - Study of High Dose Intravenous (IV) Ascorbic Acid in Measurable Solid Tumor Disease Phase 2
Enrolling by invitation NCT05266196 - A Rollover Protocol to Allow for Continued Access to the LSD1 Inhibitor Seclidemstat (SP-2577) Phase 1/Phase 2
Not yet recruiting NCT06277154 - MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma Phase 2
Completed NCT00436657 - Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Cisplatin for Children With Peritoneal Cancer Phase 1
Active, not recruiting NCT01946529 - Therapeutic Trial for Patients With Ewing Sarcoma Family of Tumor and Desmoplastic Small Round Cell Tumors Phase 2
Not yet recruiting NCT02982486 - A Phase II of Nivolumab Plus Ipilimumab in Non-resectable Sarcoma and Endometrial Carcinoma Phase 2
Completed NCT02982941 - Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors Phase 1
Recruiting NCT04530487 - Donor Stem Cell Transplant After Chemotherapy for the Treatment of Recurrent or Refractory High-Risk Solid Tumors in Pediatric and Adolescent-Young Adults Phase 2
Recruiting NCT03967834 - Multimodal Immune Characterization of RAre Soft Tissue Sarcoma - MIRAS Project From SARRA (SARcome RAre) Project of the French Sarcoma Group N/A

External Links